3934-20-1 | Page 2 of 12

Scattolin, Thomas’s team published research in Organic Letters in 2022 | CAS: 3934-20-1

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Almost all organochlorine compounds are synthesized. It is widely used as intermediates, solvents and pesticides of chemical synthetic products.Synthetic Route of C4H2Cl2N2

In 2022,Scattolin, Thomas; Gharbaoui, Tawfik; Chen, Cheng-yi published an article in Organic Letters. The title of the article was 《A Nucleophilic Deprotection of Carbamate Mediated by 2-Mercaptoethanol》.Synthetic Route of C4H2Cl2N2 The author mentioned the following in the article:

Carbamates, typically used for the protection of amines, including Cbz, Alloc, and Me carbamate, was readily deprotected by treatment with 2-mercaptoethanol in the presence of potassium phosphate tribasic in N,N-dimethylacetamide at 75°C. This nucleophilic deprotection protocol was superior to the standard hydrogenolysis or Lewis acid-mediated deprotection conditions for substrates bearing a functionality sensitive to these more traditional methods.2,4-Dichloropyrimidine(cas: 3934-20-1Synthetic Route of C4H2Cl2N2) was used in this study.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Feng, Da’s team published research in Chinese Chemical Letters in 2021 | CAS: 3934-20-1

Feng, Da; Wei, Fenju; Sun, Yanying; Sharma, Prem Prakash; Zhang, Tao; Lin, Hao; Rathi, Brijesh; De Clercq, Erik; Pannecouque, Christophe; Kang, Dongwei; Zhan, Peng; Liu, Xinyong published their research in Chinese Chemical Letters in 2021. The article was titled 《Boronic acid-containing diarylpyrimidine derivatives as novel HIV-1 NNRTIs: Design, synthesis and biological evaluation》.Synthetic Route of C4H2Cl2N2 The article contains the following contents:

Drug resistance remains to be a serious problem with type I human immunodeficiency virus (HIV-1) non-nucleoside reverse transcriptase inhibitors (NNRTIs). A series of novel boronic acid-containing diarylpyrimidine (DAPY) derivatives were designed via bioisosterism and scaffold-hopping strategies, taking advantage of the ability of a boronic acid group to form multiple hydrogen bonds. The target compounds were synthesized and evaluated for their anti-HIV activities and cytotoxicity in MT-4 cells. Compound 10j yielded the most potent activity and turned out to be a single-digit nanomolar inhibitor towards the HIV-1 IIIB [wild-type (WT) strain], L100I and K103N strains, with 50% effective concentration (EC50) values of 7.19-9.85 nmol/L. Moreover, 10j inhibited the double-mutant strain RES056 with an EC50 value of 77.9 nmol/L, which was 3.3-more potent than that of EFV (EC50 = 260 nmol/L) and comparable to that of ETR (EC50 = 32.2 nmol/L). 10J acted like classical NNRTIs with high affinity for WT HIV-1 reverse transcriptase (RT) with 50% inhibition concentration (IC50) value of 0.1837μmol/L. Furthermore, mol. dynamics simulation indicated that 10j was proposed as a promising mol. for fighting against HIV-1 infection through inhibiting RT activity. Overall, the results demonstrated that 10j could serve as a lead mol. for further modification to address virus-drug resistance. In the experimental materials used by the author, we found 2,4-Dichloropyrimidine(cas: 3934-20-1Synthetic Route of C4H2Cl2N2)

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Han, Shuwen’s team published research in Bioorganic Chemistry in 2022 | CAS: 3934-20-1

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chloride content in crude oil can be detected through specialized laboratory analysis. Care and attention are essential while sampling and testing.COA of Formula: C4H2Cl2N2

In 2022,Han, Shuwen; Zhou, Wei; Zhuang, Chunlin; Chen, Fener published an article in Bioorganic Chemistry. The title of the article was 《Structure-Based design of Marine-derived Meridianin C derivatives as glycogen synthase kinase 3β inhibitors with improved oral bioavailability: From aminopyrimidyl-indoles to the sulfonyl analogues》.COA of Formula: C4H2Cl2N2 The author mentioned the following in the article:

Glycogen synthase kinase 3β (GSK-3β) has become an attractive target for the treatment of diabetes. Compound I is an indole-based GSK-3β inhibitor designed from the Meridianin C, a marine natural product (MNP) isolated from Aplidium meridianum. However, this compound has a moderate inhibitory activity toward GSK-3β (IC50 = 24.4 μM), moderate glucose uptake (38%), and especially, a low oral bioavailability (F = 11.4%). In the present study, applying the structure-based design strategy, a series of derivatives modified on the indole moiety were synthesized based on the lead compound I, followed by evaluating their cytotoxic activity, antihyperglycemic activity, and kinase inhibitory activity. Among this series, compound 6x with a sulfonyl group displayed the highest glucose uptake (83.5%) in muscle L6 cells, showing much higher inhibitory activity against GSK-3β (IC50 = 5.25 μM). Mol. docking indicated that compound 6x was properly inserted into the ATP-binding binding pocket of GSK-3β with a higher docking score (-8.145 kcal/mol) compared with that of compound I (-6.950 kcal/mol), interpreting the higher kinase inhibitory activity toward GSK-3β. Remarkably, compound 6x showed favorable drug-like properties, including significantly better oral bioavailability (F = 47.4%) and no two-week acute toxicity at a dose of 1g/kg. Our findings suggest that these MNP-derived sulfonyl indole derivatives could be used as lead compounds for the development of anti-hyperglycemic drugs. The experimental process involved the reaction of 2,4-Dichloropyrimidine(cas: 3934-20-1COA of Formula: C4H2Cl2N2)

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Bhavanam, Lourdu Rani’s team published research in ChemistrySelect in 2019 | CAS: 3934-20-1

2,4-Dichloropyrimidine(cas: 3934-20-1) is a member of organic chlorides. Organic chlorides are compounds containing a carbon-chlorine bond, which are widely used in the oil field as a wax dissolver. They are generally not present in crude oils and are typically the result of additives, cleaning solutions or chemicals used for oil recovery.Product Details of 3934-20-1

Product Details of 3934-20-1In 2019 ,《Synthesis, Characterization, Anticancer and Antimicrobial Activity Studies of Novel Isomeric 2,4-Disubstituted Ureide Derivatives of Pyrimidinopiperidines》 appeared in ChemistrySelect. The author of the article were Bhavanam, Lourdu Rani; Kotra, Vijay; Mule, Sivanagi Reddy; Krishna Khandapu, Bala Murali; Bollikolla, Hari Babu. The article conveys some information:

A series of isomeric ureide derivatives of novel 2,4-disubstituted pyrimidinopiperidines, e.g., I were synthesized starting from 2,4-dichloropyrimidine. All the final products were purified on silica and characterized by spectral anal. Both the 2,4-disubstituted pyrimidinopiperidines were analyzed for their in vitro anticancer activity on the cell lines HCT116, MIA-PaCa2 and MDA-MB 231 by using MTT cell proliferation assay. Further, the antimicrobial studies were carried out against different bacterial and fungal strains by employing cup plate method. These compounds showed significant anticancer activity on tested three cancer cell lines and exhibited potent antimicrobial activity in tested strains of bacteria and fungi. In addition to this study using 2,4-Dichloropyrimidine, there are many other studies that have used 2,4-Dichloropyrimidine(cas: 3934-20-1Product Details of 3934-20-1) was used in this study.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Manzoor, Shoaib’s team published research in Bioorganic Chemistry in 2021 | CAS: 3934-20-1

Manzoor, Shoaib; Gabr, Moustafa T.; Rasool, Bisma; Pal, Kavita; Hoda, Nasimul published their research in Bioorganic Chemistry in 2021. The article was titled 《Dual targeting of acetylcholinesterase and tau aggregation: Design, synthesis and evaluation of multifunctional deoxyvasicinone analogues for Alzheimer′s disease》.Safety of 2,4-Dichloropyrimidine The article contains the following contents:

Development of multitargeted ligands have demonstrated remarkable efficiency as potential therapeutics for Alzheimer′s disease (AD). Herein, we reported a new series of deoxyvasicinone analogs as dual inhibitor of acetylcholinesterase (AChE) and tau aggregation that function as multitargeted ligands for AD. All the multitargeted ligands 11(a-j) and 15(a-g) were designed, synthesized, and validated by 1HNMR, 13CNMR and mass spectrometry. All the synthesized compounds 11(a-j) and 15(a-g) were screened for their ability to inhibit AChE, BACE1, amyloid fibrillation, α-syn aggregation, and tau aggregation. All the screened compounds possessed weak inhibition of BACE-1, Aβ42 and α-syn aggregation. However, several compounds were identified as potential hits in the AChE inhibitory screening assay and cellular tau aggregation screening. Among all compounds, 11f remarkably inhibited AChE activity and cellular tau oligomerization at single-dose screening (10 μM). Moreover, 11f displayed a half-maximal inhibitory concentration (IC50) value of 0.91 ± 0.05 μM and half-maximal effective concentration (EC50) value of 3.83 ± 0.51 μM for the inhibition of AChE and cellular tau oligomerization, resp. In addition, the neuroprotective effect of 11f was determined in tau-expressing SH-SY5Y cells incubated with Aβ oligomers. These findings highlighted the potential of 11f to function as a multifunctional ligand for the development of promising anti-AD drugs. The results came from multiple reactions, including the reaction of 2,4-Dichloropyrimidine(cas: 3934-20-1Safety of 2,4-Dichloropyrimidine)

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Laiolo, Jeronimo’s team published research in Scientific Reports in 2021 | CAS: 3934-20-1

Reference of 2,4-DichloropyrimidineIn 2021 ,《Structure activity relationships and the binding mode of quinolinone-pyrimidine hybrids as reversal agents of multidrug resistance mediated by P-gp》 appeared in Scientific Reports. The author of the article were Laiolo, Jeronimo; Lanza, Priscila Ailin; Parravicini, Oscar; Barbieri, Cecilia; Insuasty, Daniel; Cobo, Justo; Vera, D. Mariano Adolfo; Enriz, Ricardo Daniel; Carpinella, Maria Cecilia. The article conveys some information:

P-gp-associated multidrug resistance is a major impediment to the success of chemotherapy. With the aim of finding non-toxic and effective P-gp inhibitors, we investigated a panel of quinolin-2-one-pyrimidine hybrids. Among the active compounds, two of them significantly increased intracellular doxorubicin and rhodamine 123 accumulation by inhibiting the efflux mediated by P-gp and restored doxorubicin toxicity at nanomolar range. Structure-activity relationships showed that the number of methoxy groups, an optimal length of the mol. in its extended conformation, and at least one flexible methylene group bridging the quinolinone to the moiety bearing the pyrimidine favored the inhibitory potency of P-gp. The best compounds showed a similar binding pattern and interactions to those of doxorubicin and tariquidar, as revealed by MD and hybrid QM/MM simulations performed with the recent exptl. structure of P-gp co-crystallized with paclitaxel. Anal. of the mol. interactions stabilizing the different mol. complexes determined by MD and QTAIM showed that binding to key residues from TMH 4-7 and 12 is required for inhibition. After reading the article, we found that the author used 2,4-Dichloropyrimidine(cas: 3934-20-1Reference of 2,4-Dichloropyrimidine)

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Song, Peilu’s team published research in Acta Pharmaceutica Sinica B in 2022 | CAS: 3934-20-1

In 2022,Song, Peilu; Zhao, Fan; Li, Dahong; Qu, Jiqiang; Yao, Miao; Su, Yuan; Wang, Hanxun; Zhou, Miaomiao; Wang, Yujie; Gao, Yinli; Li, Feng; Zhao, Dongmei; Zhang, Fengjiao; Rao, Yu; Xia, Mingyu; Li, Haitao; Wang, Jian; Cheng, Maosheng published an article in Acta Pharmaceutica Sinica B. The title of the article was 《Synthesis of selective PAK4 inhibitors for lung metastasis of lung cancer and melanoma cells》.Reference of 2,4-Dichloropyrimidine The author mentioned the following in the article:

The p21 activated kinase 4 (PAK4) is serine/threonine protein kinase that is critical for cancer progression. Guided by X-ray crystallog. and structure-based optimization, we report a novel subseries of C-3-substituted 6-ethynyl-1H-indole derivatives that display high potential and specificity towards group II PAKs. Among these inhibitors, compound 55 exhibited excellent inhibitory activity and kinase selectivity, displayed superior anti-migratory and anti-invasive properties against the lung cancer cell line A549 and the melanoma cell line B16. Compound 55 exhibited potent in vivo antitumor metastatic efficacy, with over 80% and 90% inhibition of lung metastasis in A549 or B16-BL6 lung metastasis models, resp. Further mechanistic studies demonstrated that compound 55 mitigated TGF-β1-induced epithelial-mesenchymal transition (EMT). In the experimental materials used by the author, we found 2,4-Dichloropyrimidine(cas: 3934-20-1Reference of 2,4-Dichloropyrimidine)

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Luo, Zaoli’s team published research in Chemistry – An Asian Journal in 2021 | CAS: 3934-20-1

Luo, Zaoli; Liu, Yungen; Tong, Ka-Chung; Chang, Xiao-Yong; To, Wai-Pong; Che, Chi-Ming published an article in 2021. The article was titled 《Luminescent Platinum(II) Complexes with Bidentate Diacetylide Ligands: Structures, Photophysical Properties and Application Studies》, and you may find the article in Chemistry – An Asian Journal.Formula: C4H2Cl2N2 The information in the text is summarized as follows:

A series of platinum(II) m-terphenyl 2,2”-diacetylide complexes supported by diimines (2,2′-bipyridines, 1,10-phenanthroline, 2,2′-bipyrimidine) or bis-N-heterocyclic carbenes 3-RIm(CH2)nImR-3′ (R = Bu, Me; n = 1-3) ligands have been prepared The diacetylide ligands adopt a cis coordination mode featuring non-planar terphenyl moieties as revealed by X-ray crystallog. analyses. The electrochem., photophys. and photochem. properties of these platinum(II) complexes have been investigated. These platinum(II) diimine complexes show broad emission with peak maxima from 566 nm to 706 nm, with two of them having emission quantum yields >60% and lifetimes <2μs in solutions at room temperature, whereas the platinum(II) diacetylide complexes having bis-N-heterocyclic carbene instead of diimine ligand display photoluminescence with quantum yields of up to 28% in solutions and excited state lifetimes of up to 62μs at room temperature Application studies revealed that one of the complexes can catalyze photoinduced aerobic dehydrogenation of alcs. and alkenes, and a relatively non-toxic water-soluble Pt(II) complex displays anti-angiogenic activity. After reading the article, we found that the author used 2,4-Dichloropyrimidine(cas: 3934-20-1Formula: C4H2Cl2N2)

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Ding, Li’s team published research in Journal of Medicinal Chemistry in 2021 | CAS: 3934-20-1

Ding, Li; Pannecouque, Christophe; De Clercq, Erik; Zhuang, Chunlin; Chen, Fen-Er published their research in Journal of Medicinal Chemistry in 2021. The article was titled 《Hydrophobic Pocket Occupation Design of Difluoro-Biphenyl-Diarylpyrimidines as Non-Nucleoside HIV-1 Reverse Transcriptase Inhibitors: from N-Alkylation to Methyl Hopping on the Pyrimidine Ring》.Application In Synthesis of 2,4-Dichloropyrimidine The article contains the following contents:

Considering the nonideal metabolic stability of the difluoro-biphenyl-diarylpyrimidine lead compound I, a series of novel alkylated difluoro-biphenyl-diarylpyrimidines were designed and synthesized based on their structure. Introducing alkyl or substituted alkyl groups on the linker region to block the potential metabolic sensitive sites generated 22 derivatives Among them, compound II with an N-Me group displayed excellent anti-HIV-1 activity and selectivity. The Me group was hopped to the central pyrimidine to occupy the small linker region and maintain the water-mediated hydrogen bond observed in the binding of compound I with RT. The resulting compound III exhibited an improved anti-HIV-1 activity, much lower cytotoxicity, and nanomolar activity toward multiple mutants. In addition, III has a better stability in human liver microsomes than I. Moreover, no apparent in vivo acute toxicity was observed in III-treated female, especially pregnant mice. This series of alkylated compounds with highly potency and safety represent a promising lead template for future discovery. The experimental process involved the reaction of 2,4-Dichloropyrimidine(cas: 3934-20-1Application In Synthesis of 2,4-Dichloropyrimidine)

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia

Ma, Bin’s team published research in Journal of Medicinal Chemistry in 2020 | CAS: 3934-20-1

《Discovery of BIIB068: A Selective, Potent, Reversible Bruton′s Tyrosine Kinase Inhibitor as an Orally Efficacious Agent for Autoimmune Diseases》 was published in Journal of Medicinal Chemistry in 2020. These research results belong to Ma, Bin; Bohnert, Tonika; Otipoby, Kevin L.; Tien, Eric; Arefayene, Million; Bai, Judy; Bajrami, Bekim; Bame, Eris; Chan, Timothy R.; Humora, Michael; MacPhee, J. Michael; Marcotte, Douglas; Mehta, Devangi; Metrick, Claire M.; Moniz, George; Polack, Evelyne; Poreci, Urjana; Prefontaine, Annick; Sheikh, Sarah; Schroeder, Patricia; Smirnakis, Karen; Zhang, Lei; Zheng, Fengmei; Hopkins, Brian T.. Application of 3934-20-1 The article mentions the following:

Autoreactive B cell-derived antibodies form immune complexes that likely play a pathogenic role in autoimmune diseases. In systemic lupus erythematosus (SLE), these antibodies bind Fc receptors on myeloid cells and induce proinflammatory cytokine production by monocytes and NETosis by neutrophils. Bruton′s tyrosine kinase (BTK) is a non-receptor tyrosine kinase that signals downstream of Fc receptors and plays a transduction role in antibody expression following B cell activation. Given the roles of BTK in both the production and sensing of autoreactive antibodies, inhibitors of BTK kinase activity may provide therapeutic value to patients suffering from autoantibody-driven immune disorders. Starting from an inhouse proprietary screening hit followed by structure-based rational design, we have identified a potent, reversible BTK inhibitor, BIIB068 (1)(I), which demonstrated good kinome selectivity with good overall drug-like properties for oral dosing, was well tolerated across preclin. species at pharmacol. relevant doses with good ADME properties, and achieved >90% inhibition of BTK phosphorylation (pBTK) in humans.2,4-Dichloropyrimidine(cas: 3934-20-1Application of 3934-20-1) was used in this study.

Referemce:
Pyrimidine | C4H4N2 – PubChem,
Pyrimidine – Wikipedia